ALK and non-small cell lung carcinoma: Conventional platinum-based chemotherapy is the standard first-line treatment for patients with advanced NSCLC without epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, or ROS proto-oncogene 1 (ROS1) fusions (Lee, 2019; Ettinger et al., 2022; Leone et al., 2023).